Skip to main content
Premium Trial:

Request an Annual Quote

DNA Electronics Licenses NAT Technology to geneOnyx for Skincare Applications

NEW YORK (GenomeWeb News) – DNA Electronics today announced a deal making its nucleic acid testing platform available to geneOnyx for cosmetic and skincare applications.

The commercial license and supply agreement provides geneOnyx access to DNA Electronics' Genalysis platform, which geneOnyx will use to analyze a person's genetic makeup to determine how that person will react to certain product ingredients.

Financial and other terms of the deal were not disclosed.

DNA Electronics said that the deal brings it into the non-in vitro diagnostic space. Pilot trials focused on the clinical diagnostics space for Genalysis are set to begin later this year.

Genalysis is a real-time, nucleic acid testing platform that delivers point-of-need results in about 30 minutes, using a sample processing kit and interchangeable test cartridges plugged into a USB stick or other electronic reader. Using a saliva sample from a mouth swab, purified, amplification-ready DNA is delivered to a complementary metal oxide semiconductor-based test cartridge, which amplifies and detects genetic signatures in the DNA.

Based in London, DNA Electronics develops electronic microchip-based tests for real-time nucleic acid detection. It has worldwide non-exclusive licensing deals with Roche's 454 Life Sciences and Life Technologies' Ion Torrent providing those firms access to parts of its technology for use in semiconductor sequencing.

geneOnyx provides cloud-based genetic analytics services and technology for cosmetic applications.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.